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Background: There is a dearth of information on the clinicopathological differences, including the molecular
subtypes, of breast carcinomas from immigrant Arab women in Europe. Therefore, the aim of our study was to
examine and compare these features in immigrant Arab/Moroccan patients with those of European women.
Methods: Included in this study were 441 cases of breast cancer: 91 Arab/Moroccan women and 350 European
women. Age, size, grade, node involvement, and immunohistochemical profile (classification into the following
subtypes: luminal A, luminal B, HER2 +/ER -, and triple negative) were analyzed.
Results: The average age of breast cancer presentation in Arab women is almost a decade earlier than in European
women (49 versus 60 years old; p = 0.00001). Arab patients also had a higher average tumor size (25 mm versus
19 mm; p =0,008) and more grade 3 and less grade 1 tumors (p = 0.02). It should be noted, however, that this
variability in the size and grade do not appear statistically significant when compared in Arab and European
patients under 50 years old. In contrast, independent of age, the immunohistochemical subtypes were different
between the two populations, with a greater number of luminal B subtype and fewer luminal A subtype (p <0.02)
in Arab patients.
Conclusions: Arab patients with breast carcinoma have different clinicopathological features from European
patients, mainly the age of cancer presentation. Their immunohistochemical profile is also different, with more
luminal B and less luminal A subtypes, suggesting that there are not only clinicopathological differences but also
disparities in the expression profiling in these women.
Virtual slide: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
2104813621113288.
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In Belgium, breast cancer accounts for almost 13% of all
cancers and each year 9,400 new cases are observed. Its
incidence is estimated at 146/100,000 [1]. The origin of
this cancer is likely multifactorial and many factors have
been implicated, including the woman’s reproductive
lifestyle, endogenous hormones, exogenous hormones,
adiposity, physical activity, nutrition, alcohol consump-
tion, smoking, environmental toxins, and genetic suscep-
tibility in inherited syndromes [2]. Breast cancer rates* Correspondence: Jean-Christophe.Noel@erasme.ulb.ac.be
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stated.also differ by race and ethnicity [3]. It has been sugges-
ted that breast cancer in Arab populations has specific
morphological and molecular characteristics, including
poorly differentiated pathological features and increased
HER2 overexpression [4]. Naturally, Arab populations
are not homogeneous and have genetic diversity [5].
However, in a recent publication El Fatemi et al. demon-
strated that in a Moroccan Arab population, the luminal
B subtype was the most prevalent [6]. These studies,
however, were performed on the indigenous population,
and there are no data on the Moroccan Arab immigrantd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Clinicopathological characteristics of the breast
cancer patients (all ages combined)
European Arabic/Moroccan P-value
Number 350 91
Mean age (SD) 60 (13) 49 (11) 0.00001
Mean size (SD) 19 (14) 25 (18) 0.008
pT
< 20 mm 216 (62%) 45 (49%) 0.04
≥ 20 mm 134 (38%) 46 (51%)
Tumor grade
G1 69 (20%) 7 (8%) 0.02
G2 169 (48%) 41 (45%) NS
G3 112 (32%) 43 (47%) 0.01
Nodes
N positive 78 (22%) 26 (29%) NS
N Negative 272 (78%) 65 (71%)
Estrogen receptors
Positive (>1%) 301 (86%) 72 (79%) NS
Negative 49 (14%) 19 (21%)
Progesterone receptors
Positive (>1%) 266 (76%) 58 (64%) 0.02
Negative 84 (24%) 33 (36%)
Mean Ki-67 (SD) 20 (14) 27 (20) 0.003
Molecular classification
Luminal A 160 (46%) 21 (23%) 0.001
Luminal B 141 (40%) 51 (56%) 0.02
HER2 17 (5%) 5 (6%) NS
Triple negative 32 (9%) 14 (15%) NS
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grant population is the most common at our institution,
the aim of this study was to define the morphological
and immunohistochemical (surrogates to molecular clas-
ses) characteristics of breast carcinomas in these immi-
grant Moroccan Arab patients and compare them with
the European native population.
Materials and methods
Breast carcinoma specimens in formalin-fixed, paraffin-
embedded tissue blocks from 441 female patients diag-
nosed with invasive carcinoma from january 2008 to
december 2012 were retrieved from the archives of the
Department of Pathology, Erasme University Hospital.
This study was approved by the local ethics committee
(Erasme University Hospital, reference number: 2013/027)
and included 350 European white women and 91 Moroccan
Arab patients. The pathological stage and histological
grade were defined according to the criteria of the World
Health Organization 2012 [7]. The estrogen receptor (ER),
progesterone receptor (PR), Ki-67 labeling index, and
HER2 expression were evaluated at the time of the ori-
ginal diagnosis by immunohistochemistry, as previously
described [8-10]. A clinically positive test for the receptors
is defined as nuclear staining in ≥1% of the tumor cells
[8]. HER2 immunoreactivity was performed using the Or-
acle HER2 test (clone CB11; Leica Microsystems GmbH,
Wetzlar, Germany) according to the manufacturer’s in-
structions, as previously described [10]. The scoring was
assessed with the recommendations of the American So-
ciety of Clinical Oncology [11]. All of the HER2 scores of
2+ and 3+ were analyzed using the fluorescent in situ
hybridization (FISH) PathVysion HER2 DNA test (Abbott
laboratories, Abbott Park, USA) according to the manu-
facturer’s instructions. Signal ratios (HER2/CEP17) of ≥2
were classified as amplified. In this study, only 2+ and 3+
tumors with a HER2 FISH amplification were considered
as a positive result. A subtype immunohistochemical clas-
sification (surrogates to molecular classes) was adopted to
characterize the tumors, using the following criteria:
Luminal A, when either one or both of the ER and PR were
present, HER2 was negative and Ki-67 <14%; Luminal B,
when ER and/or PR were present and either Ki-67 ≥14% or
HER2 was positive; HER2 positive, when ER and PR were
absent and HER2 was positive irrespective of the Ki-67;
and Triple negative, when ER and PR were absent and
HER2 was negative. The correlation analysis was con-
ducted using the χ2 test and Fisher’s exact probably test.
For the comparison of the means, the student’s t-test was
used. Results were considered significant when p <0.05.
Results
The clinicopathological characteristics of the 441 pa-
tients are summarized in the Table 1. Arab/Moroccanpatients were characterized by an average age of pre-
sentation for breast cancer almost a decade earlier than
in European individuals (49 versus 60 years old; p =
0.00001). In addition, the size of the tumor in these pa-
tients was larger (25 mm versus 19 mm; p = 0.008), the
incidence of grade 3 tumors more frequent (p = 0.01),
the grade 1 less frequent (p = 0.02), the percentage of PR
positive lesions was less (p = 0.02), the mean Ki-67 index
was higher (27% versus 20%; p = 0.003), the Luminal A
tumor was less frequent (p = 0.001), and the Luminal B
was more frequent (p = 0.02). To ensure these results
were not biased by the age at the time of the presenta-
tion of cancer, we only extracted premenopausal patients
from this series. This enabled us able to compare groups
with an almost identical age (43 versus 42 years old). In-
terestingly, despite these adjustments, the Arab/Moroccan
patients continued to display less Luminal A tumors (p =
0.01) and more Luminal B tumors (p = 0.02) (Table 2)
(Figure 1).




Mean age (SD) 43 (4) 42 (15) NS
Mean size (SD) 22 (14) 24 (17) NS
pT
< 20 mm 47 (55%) 30 (54%) NS
≥ 20 mm 39 (45%) 26 (46%)
Tumor grade
G1 12 (14%) 1 (2%) 0.02
G2 42 (49%) 27 (48%) NS
G3 32 (37%) 28 (50%) NS
Nodes
N positive 23 (27%) 18 (32%) NS
N Negative 63 (73%) 38 (68%)
Estrogen receptors
Positive (>1%) 71 (83%) 45 (80%) NS
Negative 15 (17%) 11 (20%)
Progesterone receptors
Positive (>1%) 61 (71%) 37 (66%) NS
Negative 25 (29%) 19 (34%)
Mean Ki-67 (SD) 24 (18) 29 (20) 0.04
Molecular classification
Luminal A 35 (41%) 10 (18%) 0.01
Luminal B 36 (42%) 35 (63%) 0.02
HER2 4 (4%) 3 (5%) NS
Triple negative 11 (13%) 8 (14%) NS
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The study of possible ethnic differences in breast cancer
has mainly occurred in the United States [12]. Recently,
new data have been described for Arab populations, but
the true prevalence of breast cancer remains uncertainFigure 1 Immunohistochemical profile surrogates of the molecular cl[4,13-17]. For the majority of these studies, which were
performed only on indigenous populations, some cli-
nicopathological features are repeatedly observed: the
age of cancer presentation is a decade earlier than in
European or US patients, the average size of the lesions
is often greater than 20 mm, and the grade of tumors is
often higher. Interestingly, these data were corroborated
in our study of Arab/Moroccan immigrants. Indeed, in
our series, the mean age of presentation of breast cancer
was 49 years old in Moroccan patients and occurred al-
most a decade earlier than in European patients (mean
age: 60 years old; p = 0.00001) (Table 1). These data are
similar to those recently published by Chouchane et al.
in a review article, in which the mean age of presenta-
tion of breast cancer for Arab patients was 48 years old,
compared to 63 years old in European women. These
authors also observed that two-thirds of the Arab pa-
tients with breast cancer are younger than 50 years old
[4]. We found similar results with our Arab immigrant
population. Indeed, 61% of the Arab patients with cancer
were less than 50 years old, compared to only 24% in
the European population (p = 0.0001) (Table 2). How-
ever, these results should be interpreted with caution as
they may simply reflect that the immigrant population is
on average younger than the European population and
that the Arab older patients have a different perception
of breast cancer and therefore do not participate in the
screening program. These challenges and barriers to
breast cancer screening in Arab women have been dem-
onstrated in several studies [17-19].
The second observation on Arab patients frequently
found in the literature is the presence of larger tumors
(mean tumor size greater than 20 mm) and a higher
grade (grade 3) at diagnosis [20,21]. We were able to
confirm these findings in the general population used in
our study. Indeed, over 50% of the Arab patients had
tumors larger than 20 mm, compared to 38% of the
European patients with a tumor greater or equal to 20 mm
(p = 0.04). Furthermore, the average tumor size was 25 mmasses in premenopausal women (in percentage).
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(p = 0.008) (Table 1). We also demonstrated that the Arab
patients had an increased incidence in grade 3 tumors (p =
0.01) and fewer grade 1 tumors (p = 0.01) than Europeans.
However, the data concerning the tumor size and
grade are only statistically significant in the general po-
pulation, with all ages combined. Indeed, if we restrict
our analysis to the premenopausal women under 50
years old, the differences in the tumor size and grade are
less obvious (Table 2). This phenomenon is consistent
with recent publications that establish a strong link be-
tween age at diagnosis and the size and/or grade of the
tumor [7,22]. Molecular subtyping of breast cancer gene
expression has resulted in a better understanding of
breast carcinoma and several distinctive breast carcin-
oma molecular subtypes have been identified [22,23]. In
addition to this gene expression analysis, immunohisto-
chemical surrogates have been used for breast cancer
classification with relatively good reproducibility [24]. In
the present work, we demonstrated that the luminal sub-
type B was the most common in an Arab/Moroccan im-
migrant population. This subtype was found in 56% of
the women in the general population but only in 40% of
the European women (p = 002) (Table 1). In contrast,
the luminal A subtype was significantly more common
in the European (46% than in the Arab patients (23%;
p = 0.001). Interestingly, these statistically significant dif-
ferences in the incidence of luminal A and B subtypes be-
tween the two populations were also seen in patients
under 50 years old (Table 2). However, no differences were
observed for the subtypes HER2 and triple negative. Our
results corroborate the study performed on a native popu-
lation in Morocco, where the luminal B subtype was also
the most common [6]. Deregulation in both genomic and/
or proteomic expression of cytokeratin 8/18 and TFAP2C
(a member of the AP-2 family) has been shown to regulate
expression of the ER, and the RET proto-oncogene might
contribute to the high proportion of the luminal B subtype
observed in Arab women. However, this observation
should be confirmed in future studies [25].
Conclusions
Arab immigrant patients with breast carcinoma have dif-
ferent clinicopathological features from those of European
women. In particular, the average age at presentation is al-
most a decade earlier than in European women and ap-
pears as a key factor that at least partially explains the
other variable modifications, including the lesion size and
histological grade. Moreover, independent of age, the im-
munohistochemical profile of the molecular classes is dif-
ferent, with more luminal B and less luminal A subtypes,
suggesting that there are clinicopathological differences,
as well as disparities in the expression profiling in these
women.Abbreviations
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